Thymic remodeling associated with hyperplasia in myasthenia gravis

Autoimmunity

Volumn 43, Issue 5-6, 2010, Pages 401-412

  Le Panse, Rozen ^a,b   Bismuth, Jacky ^a,b   Cizeron Clairac, Géraldine ^a,b   Weiss, Julia Miriam ^a,b   Cufi, Perrine ^a,b   Dartevelle, Philippe ^a   De Rosbo, Nicole Kerlero ^a,b   Berrih Aknin, Sonia ^a,b  

^a CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

chemokines; germinal centers; inflammation; Myasthenia; thymus

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CD31 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHOLINERGIC RECEPTOR ANTIBODY; CORTICOSTEROID; CXCL13 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOCORTICOID; HOMEODOMAIN PROTEIN; INTERFERON; INTERFERON ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; PROSPERO HOMEOBOX PROTEIN 1; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTOME; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ANTIBODY TITER; AUTOIMMUNITY; B LYMPHOCYTE; CELL MIGRATION; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; EPITHELIUM CELL; EXTRACELLULAR MATRIX; GERMINAL CENTER; HOMEOSTASIS; HUMAN; LYMPHANGIOGENESIS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTIC INFILTRATION; MYASTHENIA GRAVIS; PERIPHERAL LYMPHOCYTE; PROTEIN EXPRESSION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THYMECTOMY; THYMIC REMODELING; THYMUS; THYMUS ENDOTHELIAL CELL; THYMUS FUNCTION; THYMUS HYPERPLASIA; UPREGULATION; VASCULAR ENDOTHELIUM; VENULE;

ANIMALS; AUTOANTIBODIES; CHEMOKINES; EPITHELIAL CELLS; HUMANS; HYPERPLASIA; INTERFERONS; LYMPHANGIOGENESIS; MYASTHENIA GRAVIS; NEOVASCULARIZATION, PATHOLOGIC; NEUROMUSCULAR JUNCTION; RECEPTORS, NICOTINIC; THYMUS GLAND;

EID: 77955874378     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916930903563491     Document Type: Review

References (113)

1. Vrolix K, Fraussen J, Molenaar P, Losen M, Somers V, Stinissen P, De Baets M, Mart́nez-Mart́nez P. The autoantigen repertoire in myasthenia gravis. Autoimmunity 2010; 43(5):380-400.
2. Aharonov A, Abramsky O, Tarrab-Hazdai R, Fuchs S. Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis. Lancet 1975;2(7930):340-342.
3. HochW, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature Med 2001;7(3): 365-368.
4. Evoli A, Batocchi AP, Lo Monaco M, Servidei S, Padua L, Majolini L, Tonali P. Clinical heterogeneity of seronegative myasthenia gravis. Neuromuscul Disord 1996;6(3): 155-161.
5. Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A. IgG1 antibodies to acetylcholine receptors in "seronegative" myasthenia gravis. Brain 2008;131(Pt 7):1940-1952. (Pubitemid 351957451)
6. Berrih-Aknin S, Eymard B. Thymus et pathologies. Biologie 1999;5(7):579-585.
7. Derbinski J, Gabler J, Brors B, Tierling S, Jonnakuty S, Hergenhahn M, Peltonen L,Walter J,Kyewski B. Promiscuous gene expression in thymic epithelial cells is regulated at multiple levels. J Exp Med 2005;202(1):33-45.
8. Cabarrocas J, Cassan C, Magnusson F, Piaggio E, Mars L, Derbinski J, Kyewski B, Gross DA, Salomon BL, Khazaie K, Saoudi A, Liblau RS. Foxp3+ CD25+ regulatory T cells specific for a neo-self-antigen develop at the double-positive thymic stage. Proc Natl Acad Sci USA 2006;103(22): 8453-8458.
9. Levinson AI, Wheatley LM. The thymus and the pathogenesis of myasthenia gravis. Clin Immunol Immunopathol 1996;78(1):1-5.
10. Berrih-Aknin S, Morel E, Raimond F, Safar D, Gaud C, Binet J, Levasseur P, Bach J. The role of the thymus in myasthenia gravis: Immunohistological and immunological studies in 115 cases. Ann N Y Acad Sci 1987;505:50-70.
11. Kuks JB, Oosterhuis HJ, Limburg PC, The TH. Antiacetylcholine receptor antibodies decrease after thymectomy in patients with myasthenia gravis. Clinical correlations. J Autoimmun 1991;4(2):197-211.
12. Wakkach A, Guyon T, Bruand C, Tzartos S, Cohen- Kaminsky S, Berrih-Aknin S. Expression of acetylcholine receptor genes in human thymic epithelial cells: Implications for myasthenia gravis. J Immunol 1996;157(8):3752-3760.
13. Safar D, Berrih-Aknin S, Morel E. In vitro anti-acetylcholine receptor antibody synthesis by myasthenia gravis patient lymphocytes: Correlations with thymic histology and thymic epithelial-cell interactions. J Clin Immunol 1987;7(3): 225-234.
14. Leprince C, Cohen-Kaminsky S, Berrih-Aknin S, Vernet-Der Garabedian B, Treton D, Galanaud P, Richard Y. Thymic B cells from myasthenia gravis patients are activated B cells. Phenotypic and functional analysis. J Immunol 1990;145(7): 2115-2122.
15. Melms A, Schalke BC, Kirchner T, Muller-Hermelink HK, Albert E, Wekerle H. Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. J Clin Invest 1988;81(3):902-908.
16. Meinl E, KlinkertWE,Wekerle H. The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat. Am J Pathol 1991;139(5):995-1008.
17. Papatestas AE, Alpert LI, Osserman KE, Osserman RS, Kark AE. Studies in myasthenia gravis: Effects of thymectomy. Results on 185 patients with nonthymomatous and thymomatous myasthenia gravis, 1941-1969. Am J Med 1971;50(4):465-474.
18. Ponseti JM, Caritg N, Gamez J, Lopez-Cano M, Vilallonga R, Armengol M. A comparison of long-term post-thymectomy outcome of anti-AChR-positive, anti-AChR-negative and anti-MuSK-positive patients with non-thymomatous myasthenia gravis. Expert Opin Biol Ther 2009;9(1):1-8.
19. Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, Marino M, Bartoccioni E. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126(Pt 10):2304-2311.
20. Leite MI, Strobel P, Jones M, Micklem K, Moritz R, Gold R, Niks EH, Berrih-Aknin S, Scaravilli F, Canelhas A, Marx A, Newsom-Davis J, Willcox N, Vincent A. Fewer thymic changes in MuSK antibody-positive than in MuSK antibodynegative MG. Ann Neurol 2005;57(3):444-448.
21. Lauriola L, Ranelletti F, Maggiano N, Guerriero M, Punzi C, Marsili F, Bartoccioni E, Evoli A. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005;64(3):536-538.
22. Meraouna A, Cizeron-Clairac G, Le Panse R, Bismuth J, Truffault F, Talaksen C, Berrih-Aknin S. The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 2006;108(2):432-440.
23. Le Panse R, Cizeron-Clairac G, Cuvelier M, Truffault F, Bismuth J, Nancy P, De Rosbo NK, Berrih-Aknin S. Regulatory and pathogenic mechanisms in human autoimmune myasthenia gravis. Ann N Y Acad Sci 2008;1132: 135-142.
24. Bofill M, Janossy G, WillcoxN, Chilosi M, Trejdosiewicz LK, Newsom-Davis J. Microenvironments in the normal thymus and the thymus in myasthenia gravis. Am J Pathol 1985; 119(3):462-473.
25. Berrih S, Savino W, Cohen S. Extracellular matrix of the human thymus: Immunofluorescence studies on frozen sections and cultured epithelial cells. J Histochem Cytochem 1985;33(7):655-664.
26. Berrih S, Morel E, Gaud C, Raimond F, Le Brigand H, Bach JF. Anti-AChR antibodies, thymic histology, and T-cell subsets in myasthenia gravis. Neurology 1984;34(1):66-71.
27. Flores KG, Li J, Hale LP. B cells in epithelial and perivascular compartments of human adult thymus. Hum Pathol 2001; 32(9):926-934.
28. Bradfield JW. Altered venules in the stimulated human thymus as evidence of lymphocyte recirculation. Clin Exp Immunol 1973;13(2):243-252.
29. Vetters M, Barclay RS. The incidence of germinal centres in thymus glands of patients with congenital heart disease. J Clin Pathol 1973;26(8):583-591.
30. Murakami M, Hosoi Y, Negishi T, Kamiya Y, Miyashita K, Yamada M, Iriuchijima T, Yokoo H, Yoshida I, Tsushima Y, Mori M. Thymic hyperplasia in patients with Graves' disease. Identification of thyrotropin receptors in human thymus. J Clin Invest 1996;98(10):2228-2234.
31. Le Panse R, Cizeron-Clairac G, Bismuth J, Berrih Aknin S. Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CCL21 in thymic hyperplasia. J Immunol 2006; 177:7868-7879.
32. Le Panse R, Cizeron-Clairac G, Cuvelier M, Truffault F, Bismuth J, Nancy P, Kerlero De Rosbo N, Berrih-Aknin S. Regulatory and pathogenic mechanisms in autoimmune myasthenia gravis. Ann N Y Acad Sci 2008;1132:135-142.
33. McLachlan SM, Nicholson LV, Venables G, Mastalgia FL, Bates D, Smith BR, Hall R. Acetylcholine receptor antibody synthesis in lymphocyte cultures. J Clin Lab Immunol 1981; 5(3):137-142.
34. Cizeron-Clairac G, LePanse R, Frenkian-Cuvelier M, Meraouna A, Truffault F, Bismuth J, Mussot S, Kerlero De Rosbo N, Berrih-Aknin S. Thymus and myasthenia gravis: What can we learn from DNA microarrays? J Neuroimmunol 2008;201-202:57-63.
35. Sims GP, Shiono H, Willcox N, Stott DI. Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis. J Immunol 2001;167(4):1935-1944.
36. Guigou V, Emilie D, Berrih-Aknin S, Fumoux F, Fougereau M, Schiff C. Individual germinal centres of myasthenia gravis human thymuses contain polyclonal activated B cells that express all the Vh and Vk families. Clin Exp Immunol 1991;83(2):262-266.
37. Soderstrom N, Axelsson JA, Hagelqvist E. Postcapillary venules of the lymph node type in the thymus in myasthenia. Lab Invest 1970;23(5):451-458.
38. Girard JP, Springer TA. High endothelial venules (HEVs): Specialized endothelium for lymphocyte migration. Immunol Today 1995;16(9):449-457.
39. Berrih-Aknin S, Ruhlmann N, Bismuth J, Cizeron-Clairac G, Zelman E, Shachar I, Dartevelle P, KerlerodeRosbo N, LePanse R. CCL21 overexpressed on lymphatic vessels drives thymic hyperplasia in myasthenia. Ann Neurol 2009;66(4): 521-531.
40. Haig DM, Hopkins J, Miller HR. Local immune responses in afferent and efferent lymph. Immunology 1999;96(2): 155-163.
41. Angeli V, Ginhoux F, Llodra J, Quemeneur L, Frenette PS, Skobe M, Jessberger R, Merad M, Randolph GJ. B-celldriven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity 2006;24(2):203-215.
42. Nibbs RJ, Kriehuber E, Ponath PD, Parent D, Qin S, Campbell JD, Henderson A, Kerjaschki D, Maurer D, Graham GJ, Rot A. The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors. Am J Pathol 2001;158(3):867-877.
43. Pearse G. Normal structure, function and histology of the thymus. Toxicol Pathol 2006;34(5):504-514.
44. Nagane Y, Utsugisawa K, Obara D, Yamagata M, Tohgi H. Dendritic cells in hyperplastic thymuses from patients with myasthenia gravis. Muscle Nerve 2003;27(5):582-589.
45. Cohen-Kaminsky S, Berrih-Aknin S. Production of interleukin 1 (IL1) by human thymic epithelial cells (TEC). Adv Exp Med Biol 1988;237:299-305.
46. Emilie D, Crevon MC, Cohen-Kaminsky S, Peuchmaur M, Devergne O, Berrih-Aknin S, Galanaud P. In situ production of interleukins in hyperplastic thymus from myasthenia gravis patients. Hum Pathol 1991;22(5):461-468.
47. Cohen-Kaminsky S, Devergne O, Delattre RM, Klingel- Schmitt I, Emilie D, Galanaud P, Berrih-Aknin S. Interleukin-6 overproduction by cultured thymic epithelial cells from patients with myasthenia gravis is potentially involved in thymic hyperplasia. Eur Cytokine Netw 1993; 4(2):121-132. (Pubitemid 23170950)
48. Colombara M, Antonini V, Riviera AP, Mainiero F, Strippoli R, Merola M, Fracasso G, Poffe O, Brutti N, Tridente G, Colombatti M, Ramarli D. Constitutive activation of p38 and ERK1/2 MAPKs in epithelial cells of myasthenic thymus leads to IL-6 and RANTES overexpression: Effects on survival and migration of peripheral Tand B cells. J Immunol 2005;175(10):7021-7028.
49. Bernasconi P, Passerini L, Annoni A, Ubiali F, Marcozzi C, Confalonieri P, Cornelio F, Mantegazza R. Expression of transforming growth factor-beta1 in thymus of myasthenia gravis patients: Correlation with pathological abnormalities. Ann N Y Acad Sci 2003;998:278-283.
50. BalandinaA, Lecart S,Dartevelle P, SaoudiA,Berrih-Aknin S. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 2005;105(2):735-741.
51. Salmon AM, Bruand C, Cardona A, Changeux JP, Berrih-Aknin S. An acetylcholine receptor alpha subunit promoter confers intrathymic expression in transgenic mice. Implications for tolerance of a transgenic self-antigen and for autoreactivity in myasthenia gravis. J Clin Invest 1998; 101(11):2340-2350.
52. Pugliese A, Zeller M, Fernandez A, Jr, Zalcberg LJ, Bartlett RJ, Ricordi C, Pietropaolo M, Eisenbarth GS, Bennett ST, Patel DD. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997;15(3):293-297.
53. Mesnard-Rouiller L, Bismuth J, Wakkach A, Poea-Guyon S, Berrih-Aknin S. Thymic myoid cells express high levels of muscle genes. J Neuroimmunol 2004;148(1-2):97-105.
54. Zheng Y, Wheatley LM, Liu T, Levinson AI. Acetylcholine receptor alpha subunit mRNA expression in human thymus: Augmented expression in myasthenia gravis and nupregulation by interferon-gamma. Clin Immunol 1999; 91(2):170-177.
55. Drenckhahn D, von Gaudecker B, Muller-Hermelink H, Unsicker K, Groschel-Stewart U. Myosin and actin containing cells in the human postnatal thymus. Ultrastructural and immunohistochemical findings in normal thymus and in myasthenia gravis. Virchows Arch B Cell Pathol Mol Pathol 1979;23(1):33-45.
56. Wakkach A, Poea S, Chastre E, Gespach C, Lecerf F, De La Porte S, Tzartos S, Coulombe A, Berrih-Aknin S. Establishment of a human thymic myoid cell line. Phenotypic and functional characteristics. Am J Pathol 1999;155(4): 1229-1240.
57. Leite MI, Jones M, Strobel P, Marx A, Gold R, Niks E, Verschuuren JJ, Berrih-Aknin S, Scaravilli F, Canelhas A, Morgan BP, Vincent A, Willcox N. Myasthenia gravis thymus: Complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol 2007;171(3):893-905.
58. Roxanis I, Micklem K, McConville J, Newsom-Davis J, Willcox N. Thymic myoid cells and germinal center formation in myasthenia gravis; possible roles in pathogenesis. J Neuroimmunol 2002;125(1-2):185-197.
59. Poeä-Guyon S, Christadoss P, Le Panse R, Guyon T, De BaetsM,Wakkach A, Bidault J, Tzartos S, Berrih-Aknin S. Effects of cytokines on acetylcholine receptor expression: Implications for myasthenia gravis. J Immunol 2005;174(10): 5941-5949. (Pubitemid 40663780)
60. Confalonieri P, Antozzi C, Cornelio F, Simoncini O, Mantegazza R. Immune activation in myasthenia gravis: Soluble interleukin-2 receptor, interferon-gamma and tumor necrosis factor-alpha levels inpatients'serum. JNeuroimmunol 1993;48(1):33-36.
61. Yoshikawa H, Satoh K, Yasukawa Y, Yamada M. Cytokine secretion by peripheral blood mononuclear cells in myasthenia gravis. J Clin Neurosci 2002;9(2):133-136.
62. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197(6):711-723.
63. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, OrtmannWA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100(5): 2610-2615.
64. Bolinger AM, Taeubel MA. Recombinant interferon gamma for treatment of chronic granulomatous disease and other disorders. Clin Pharm 1992;11(10):834-850, quiz 92-94.
65. Piccolo G, Franciotta D, Versino M, Alfonsi E, Lombardi M, Poma G. Myasthenia gravis in a patient with chronic active hepatitis C during interferon-alpha treatment. J Neurol Neurosurg Psych 1996;60(3):348.
66. Mase G, Zorzon M, Biasutti E, Vitrani B, Cazzato G, Urban F, Frezza M. Development of myasthenia gravis during interferon-alpha treatment for anti-HCV positive chronic hepatitis. J Neurol Neurosurg Psych 1996;60(3): 348-349.
67. Dionisiotis J, Zoukos Y, Thomaides T. Development of myasthenia gravis in two patients with multiple sclerosis following interferon beta treatment. J Neurol Neurosurg Psych 2004;75(7):1079.
68. Batocchi AP, Evoli A, Servidei S, Palmisani MT, Apollo F, Tonali P. Myasthenia gravis during interferon alpha therapy. Neurology 1995;45(2):382-383.
69. Meager A, Wadhwa M, Dilger P, Bird C, Thorpe R, Newsom-Davis J, Willcox N. Anti-cytokine autoantibodies in autoimmunity: Preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol 2003;132(1):128-136.
70. Meloni A, Furcas M, Cetani F, Marcocci C, Falorni A, Perniola R, Pura M, Boe Wolff AS, Husebye ES, Lilic D, Ryan KR, Gennery AR, Cant AJ, Abinun M, Spickett GP, Arkwright PD, Denning D, Costigan C, Dominguez M, McConnell V, Willcox N. Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2008;93(11):4389-4397.
71. SavinoW. The thymus is a common target organ in infectious diseases. PLoS Pathog 2006;2(6):e62.
72. Bach JF. Infections and autoimmune diseases. J Autoimmun 2005;25S:74-80.
73. Schwimmbeck PL, Dyrberg T, Drachman DB, OldstoneMB. Molecular mimicry and myasthenia gravis. An autoantigenic site of the acetylcholine receptor alpha-subunit that has biologic activity and reacts immunochemically with herpes simplex virus. J Clin Invest 1989;84(4):1174-1180.
74. Kott E, Hahn T, Huberman M, Levin S, Schattner A. Interferon system and natural killer cell activity in myasthenia gravis. Q J Med 1990;76(281):951-960.
75. Colonna M. Toll-like receptors and IFN-alpha: Partners in autoimmunity. J Clin Invest 2006;116(9):2319-2322.
76. Wagner H. Endogenous TLR ligands and autoimmunity. Adv Immunol 2006;91:159-173.
77. Bernasconi P, Barberis M, Baggi F, Passerini L, Cannone M, Arnoldi E, Novellino L, Cornelio F, Mantegazza R. Increased toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution. Am J Pathol 2005;167(1):129-139.
78. Gu D, Wogensen L, Calcutt NA, Xia C, Zhu S, Merlie JP, Fox HS, Lindstrom J, Powell HC, Sarvetnick N. Myasthenia gravis-like syndrome induced by expression of interferon gamma in the neuromuscular junction. J Exp Med 1995; 181(2):547-557.
79. Balasa B, Deng C, Lee J, Bradley LM, Dalton DK, Christadoss P, Sarvetnick N. Interferon gamma (IFNgamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J Exp Med 1997;186(3):385-391.
80. Zhang GX, Xiao BG, Bai XF, Van Der Meide PH, Orn A, Link H. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J Immunol 1999;162(7):3775-3781.
81. Chang JH, Kim YJ, Han SH, Kang CY. IFN-gamma-STAT1 signal regulates the differentiation of inducible Treg: Potential role for ROS-mediated apoptosis. Eur J Immunol 2009;39(5):1241-1251.
82. Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science 1999;286(5447):2098-2102.
83. LeglerDF,LoetscherM,RoosRS,Clark-Lewis I,BaggioliniM, Moser B. B-cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 1998;187(4): 655-660.
84. Weyand CM, Goronzy JJ. Ectopic germinal center formation in rheumatoid synovitis. Ann N Y Acad Sci 2003;987: 140-149.
85. Ishikawa S, Matsushima K. Aberrant B1-cell trafficking in a murine model for lupus. Front Biosci 2007;12:1790-1803.
86. Saito R, Onodera H, Tago H, Suzuki Y, Shimizu M, Matsumura Y, Kondo T, Itoyama Y. Altered expression of chemokine receptor CXCR5 on T cells of myasthenia gravis patients. J Neuroimmunol 2005;170(1-2):172-178.
87. Moser B, Schaerli P, Loetscher P. CXCR5(+) T cells: Follicular homing takes center stage in T-helper-cell responses. Trends Immunol 2002;23(5):250-254.
88. Annunziato F, Romagnani P, Cosmi L, Lazzeri E, Romagnani S. Chemokines and lymphopoiesis in human thymus. Trends Immunol 2001;22(5):277-281.
89. Liu C, Ueno T, Kuse S, Saito F, Nitta T, Piali L, Nakano H, Kakiuchi T, Lipp M, Hollander GA, Takahama Y. The role of CCL21 in recruitment of T-precursor cells to fetal thymi. Blood 2005;105(1):31-39.
90. Ueno T, Hara K, Willis MS, Malin MA, Hopken UE, Gray DH, Matsushima K, Lipp M, Springer TA, Boyd RL, Yoshie O, Takahama Y. Role for CCR7 ligands in the emigration of newly generated T lymphocytes from the neonatal thymus. Immunity 2002;16(2):205-218.
91. Berrih-Aknin S, Cohen-Kaminsky S, Truffault F. T-cell receptor expression in the thymus from patients with myasthenia gravis. Ann N Y Acad Sci 1995;756:438-440.
92. Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci USA 1998;95(1): 258-263.
93. Bromley SK, Thomas SY, Luster AD. Chemokine receptor CCR7 guides T-cell exit from peripheral tissues and entry into afferent lymphatics. Nat Immunol 2005;6(9):895-901.
94. Taub DD, Lloyd AR, Conlon K, Wang JM, Ortaldo JR, Harada A, Matsushima K, Kelvin DJ, Oppenheim JJ. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T-cell adhesion to endothelial cells. J Exp Med 1993;177(6):1809-1814.
95. Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases. Autoimmun Rev 2009;8(5):379-383.
96. Feferman T, Maiti PK, Berrih-Aknin S, Bismuth J, Bidault J, Fuchs S, Souroujon MC. Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. J Immunol 2005;174(9):5324-5331.
97. Nagakubo D, Murai T, Tanaka T, Usui T, Matsumoto M, Sekiguchi K, Miyasaka M. A high endothelial venule secretory protein, mac25/angiomodulin, interacts with multiple high endothelial venule-associated molecules including chemokines. J Immunol 2003;171(2):553-561.
98. Kwak HB, Ha H, Kim HN, Lee JH, Kim HS, Lee S, Kim HM, Kim JY, Kim HH, Song YW, Lee ZH. Reciprocal cross-talk between RANKL and interferon-gamma- inducible protein 10 is responsible for bone-erosive experimental arthritis. Arthritis Rheum 2008;58(5):1332-1342.
99. Hikosaka Y, Nitta T, Ohigashi I, Yano K, Ishimaru N, Hayashi Y, Matsumoto M, Matsuo K, Penninger JM, Takayanagi H, Yokota Y, Yamada H, Yoshikai Y, Inoue J, Akiyama T, Takahama Y. The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity 2008;29(3):438-450.
100. White AJ, Withers DR, Parnell SM, Scott HS, Finke D, Lane PJ, Jenkinson EJ, Anderson G. Sequential phases in the development of Aire-expressing medullary thymic epithelial cells involve distinct cellular input. Eur J Immunol 2008; 38(4):942-947.
101. Bleul CC, Boehm T. Chemokines define distinct microenvironments in the developing thymus. Eur J Immunol 2000;30(12):3371-3379.
102. Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 2005;23:127-159.
103. Hernandez-Lopez C, Valencia J, Hidalgo L, Martinez VG, Zapata AG, Sacedon R, Varas A, Vicente A. CXCL12/ CXCR4 signaling promotes human thymic dendritic cell survival regulating the Bcl-2/Bax ratio. Immunol Lett 2008; 120(1-2):72-78.
104. Zaitseva M, Kawamura T, Loomis R, Goldstein H, Blauvelt A, Golding H. Stromal-derived factor 1 expression in the human thymus. J Immunol 2002;168(6):2609-2617.
105. Plotkin J, Prockop SE, Lepique A, Petrie HT. Critical role for CXCR4 signaling in progenitor localization and T-cell differentiation in the postnatal thymus. J Immunol 2003; 171(9):4521-4527.
106. Norment AM, Bogatzki LY, Gantner BN, Bevan MJ. Murine CCR9, a chemokine receptor for thymus-expressed chemokine that is up-regulated following pre-TCR signaling. J Immunol 2000;164(2):639-648.
107. Youn BS, Kim CH, Smith FO, Broxmeyer HE. TECK, an efficacious chemoattractant for human thymocytes, uses GPR-9-6/CCR9 as a specific receptor. Blood 1999;94(7): 2533-2536.
108. Annunziato F, Romagnani P, Cosmi L, Beltrame C, Steiner BH, Lazzeri E, Raport CJ, Galli G, Manetti R, Mavilia C, Vanini V, Chantry D, Maggi E, Romagnani S. Macrophage-derived chemokine and EBI1-ligand chemokine attract human thymocytes in different stage of development and are produced by distinct subsets of medullary epithelial cells: Possible implications for negative selection. J Immunol 2000;165(1):238-246.
109. Kwan J, Killeen N. CCR7 directs the migration of thymocytes into the thymic medulla. J Immunol 2004; 172(7):3999-4007.
110. Kurobe H, Liu C, Ueno T, Saito F, Ohigashi I, Seach N, Arakaki R, Hayashi Y, Kitagawa T, Lipp M, Boyd RL, Takahama Y. CCR7-dependent cortex-to-medulla migration of positively selected thymocytes is essential for establishing central tolerance. Immunity 2006;24(2):165-177.
111. Ueno T, Saito F, Gray DH, Kuse S, Hieshima K, Nakano H, Kakiuchi T, Lipp M, Boyd RL, Takahama Y. CCR7 signals are essential for cortex-medulla migration of developing thymocytes. J Exp Med 2004;200(4):493-505.
112. Poznansky MC, Olszak IT, Evans RH, Wang Z, Foxall RB, Olson DP, Weibrecht K, Luster AD, Scadden DT. Thymocyte emigration is mediated by active movement away from stroma-derived factors. J Clin Invest 2002;109(8): 1101-1110.
113. Vianello F, Kraft P, Mok YT, Hart WK, White N, Poznansky MC. A CXCR4-dependent chemorepellent signal contributes to the emigration of mature single-positive CD4 cells from the fetal thymus. J Immunol 2005;175(8): 5115-5125.